
Headquarters
Pfäffikon, CH
Investment Focus
Drug development, Biological drugs, Novel therapeutics, Oncology, Fibrotic diseases, Neurological diseases, Respiratory diseases, Inflammatory diseases, Heart failure, Kidney injury
Pureos Bioventures invests venture capital in private innovative drug development companies, with an emphasis on the next generation of biological drugs and drug formats. The firm's strategy centers on advancing innovative treatments for severe diseases to impact patients’ lives. They focus on backing great teams with development programs that can make a true difference for patients.
Track your relationship with Pureos Bioventures and manage next steps in your fundraising CRM.
Use GRID's AI-powered VC matcher to find investors that are the best fit for your startup based on sector, stage, geography, and more.
Get AI-Powered Matching Back to DirectoryBen Morgan
General Partner Board
Dominik Escher
Managing Partner
Dr. Anne Grahl
Investment Manager
Dr. Bruno Teta
Pureos Partners Board
Dr. Butrint Aliu
Analyst
Dr. Dominik Escher
Managing Partner
Dr. Dragan Grabulovski
Venture Partner
Dr. Klaus Breiner
Managing Partner
Dr. Lars Nieba
Venture Partner
Dr. Martin Münchbach
Managing Partner
Dr. Matthias Staehelin
Pureos Partners Board
Dr. Roberto Iacone
Venture Partner
Dr. Veronica Gambillara Fonck
Partner
Dr. Ximing Ding
Principal
Ian Metcalfe
Venture Partner
Karen Haith
General Partner Board
Martin Münchbach
Managing Partner and Founding Partner
Pascal Mahieux
General Partner Board
Prof. Dr. Sai Reddy
Venture Partner
Stefano Lamaro
Analyst